Study of How Low Molecular Weight Heparin Affects Blood Clotting in Pregnant Women Over Time Using Thrombin Generation Testing

What this Trial Is About

Researchers are investigating how pregnancy affects blood clotting and how low-molecular-weight heparin LMWH, a common blood thinner, works during pregnancy. Pregnancy causes changes in blood factors that increase clotting risk, which protects against bleeding during childbirth but raises the chance of venous thromboembolism VTE. The study aims to understand the balance of clotting using thrombinography, a test measuring thrombin generation, to evaluate coagulation changes over the three trimesters, postpartum, and after pregnancy. The study observes pregnant women by collecting blood samples to analyze thrombin generation before and after adding LMWH in the lab. This will track changes longitudinally through pregnancy stages and postpartum. The research focuses on how the anticoagulant effect of LMWH might vary during pregnancy due to physiological changes and explores if dose adjustments are needed to avoid under- or overdosing. Participants will have multiple blood samples taken over approximately one year to assess clotting profiles using thrombinography. Researchers will measure various parameters such as endogenous thrombin potential, lag time, peak height, time to peak, start tail, and velocity index. This detailed monitoring will help evaluate the impact of LMWH on coagulation and support future studies to optimize anticoagulant therapy in pregnant women.

THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin